

Trento, 21.10.2022

## FORMATO EUROPEO PER IL CURRICULUM VITAE



### INFORMAZIONI PERSONALI

Nome	<b>Merola Elettra</b>
Nazionalità	Italiana
Luogo di nascita	Roma

### ISTRUZIONE E LAVORO

- Occupazione attuale **Dirigente medico specialista a tempo indeterminato presso la UOSD di Gastroenterologia dell'Ospedale Grassi di Ostia (ASL RM 3)**
- Dal 02.07.2018 al 30.09.2022 **Dirigente medico specialista in Gastroenterologia a tempo indeterminato, presso la UO Gastroenterologia, Ospedale Santa Chiara di Trento, APSS, nell'ambito di un servizio multizonale.**
- Da Ott. 2018 a tutt'oggi **Membro del programma "NET Connect" sui tumori neuroendocrini (<https://net-connect.info>)**
- Dal 01/2020 a tutt'oggi **Reviewer per la McMaster Online Rating of Evidence (MORE), McMaster University (Canada)**
- Dal 15.06.2017 al 30.04.2018 **Medico specialista presso l'Università tedesca Universitätsklinikum Erlangen, Reparto Medizin 1**
- 2018 **Vincitrice del Grant europeo "ENETS Excellence Academy Fellowship Grant 2017" per il progetto internazionale dal titolo "Curative Resection in Digestive Neuroendocrine Tumors: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence"**
- Dal 01.03.2010 al 31.05.2017 **Incarichi di collaborazione professionale (Dirigente Medico) nel reparto di Gastroenterologia dell'Ospedale S. Andrea di Roma (Il facoltà di Medicina della "Sapienza", Università di Roma) come *Dirigente medico specialista in Gastroenterologia, o con autorizzazione ad attività assistenziale durante Assegno di Ricerca o Dottorato di Ricerca.***
- Dal Dic. 2014 a Giu. 2017 ***Vincitrice di due Assegni di Ricerca, Sapienza Università di Roma, con un progetto sul follow-up dei tumori neuroendocrini digestivi, sviluppato in collaborazione con l'Università di Berlino Charité Virchow Klinikum.***
- Dal Giu. 2015 a Dic. 2017 **Visiting Researcher presso l'Università di Berlino Charité Virchow Klinikum. Nel reparto di Gastroenterologia, ENETS Center of Excellence per tumori neuroendocrini (Prof. Wiedenmann, Prof. Pavel)**
- Dal 2009 a luglio 2013 **Dottorato di ricerca in Oncologia Digestiva presso la II facoltà di Medicina e Chirurgia della "Sapienza", Università di Roma (Ospedale S. Andrea).**
- Dal 2005 al 2009 **Scuola di specializzazione in Gastroenterologia presso la II facoltà di Medicina e Chirurgia della "Sapienza", Università di Roma (Ospedale S. Andrea).  
**70/70 e lode.****

- Dal 1999 al 2005 Corso di Laurea specialistica in Medicina e Chirurgia presso l'Università Campus Bio Medico di Roma (laurea il 19.07.2005, 110/110 e lode)  
Tesi di laurea sperimentale in Gastroenterologia dal titolo: "Studio di marcatori del ciclo cellulare e dell'angiogenesi nell' Esofago di Barrett", nata da un Joint project con lo *Sbarro Institute for Cancer Research and Molecular Medicine* (S.H.R.O. - Temple University, Philadelphia, USA)

**Ulteriori informazioni –Attività elettive**

- Conoscenza lingua Inglese (C1); Tedesco B2 (Goethe Institut), Francese a livello scolastico.
- Corso universitario di perfezionamento su Revisioni sistematiche e metanalisi Cochrane, Università di Modena e Reggio Emilia, sede di Modena - Centro Cochrane Italiano
- Esperienze di ricerca: oncologia digestiva, neoplasie neuroendocrine, endoscopia, patologie epatiche e pancreatiche.
- Membro dei gruppi di ricerca: NET- Connect (da ottobre 2018), " Knowledge NETwork group" (2016 - 2018) e ENETS CoE Academy Fellowship EAAF (da novembre 2017)
- Internato come *visiting student* nel 2002 presso *The Department of Pathology, e presso The Division of Transplant Surgery, University of Illinois at Chicago - UIC, Chicago, IL, USA*
- Internato nel 2003 presso *The Department of Gastroenterology della Jefferson University di Philadelphia, PA, USA.*
- Internato durante i periodi estivi nel 2003 e nel 2004 presso lo *S.H.R.O. della Temple University (Philadelphia, PA, USA), con Borsa di studio dello S.H.R.O. Institute.*

**Pubblicazioni Scientifiche (papers e capitoli di libro)**

- **Merola E**, Menotti E, Branz G, et al. Hepatitis C virus burden: Treating and educating people without prejudice. *World J Hepatol.* 2022 Jul 27;14(7):1495-1503. doi: 10.4254/wjh.v14.i7.1495.
- **Merola E**, Pascher A, Rinke A, et al. ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors-Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. *Ann Surg Oncol.* 2022 Sep;29(9):5580-5581. doi: 10.1245/s10434-022-12049-3.
- Zandee WT, **Merola E**, Poczka K, et al. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres. *Eur J Cancer Care (Engl).* 2022 Jun 23:e13639. doi: 10.1111/ecc.13639.
- **Merola E**, Pascher A, Rinke A, et al. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. *Ann Surg Oncol.* 2022 Sep;29(9):5568-5577. doi: 10.1245/s10434-022-11837-1.
- **Merola E**. ASO Author Reflection: Risk of Recurrence After Radical Resection in Entero-Pancreatic Neuroendocrine Tumors. *Ann Surg Oncol.* 2022 Sep;29(9):5578-5579. doi: 10.1245/s10434-022-11882-w.
- Carlo Carnaghi, **Elettra Merola**. Treatment of Pancreatic Neuroendocrine Tumors. In: "Neuroendocrine Neoplasia Management", pag 191-199; JGiordano Beretta et al., eds. Springer Nature Switzerland AG 2021. DOI: 10.1007/978-3-030-72830-4\_14
- **Merola E**, Michielan A, Rozzanigo U, et al. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. *World J Gastrointestinal Surgery, Volume 14 Number 2 February 27, 2022, DOI: 10.4240/wjgs.v14.i2.78*
- Apostolidis L, Dal Buono A, **Merola E**, et al. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). *Cancers (Basel).* 2021 Apr 16;13(8):1936. doi: 10.3390/cancers13081936.
- **Merola E**, Michielan A, de Pretis G. Optimal timing of endoscopy for acute upper gastrointestinal bleeding: a systematic review and meta-analysis. *Intern Emerg Med.* 2021 Aug;16(5):1331-1340. doi: 10.1007/s11739-020-02563-1
- **Merola E**, Armelao F, de Pretis G. Prevalence of gastrointestinal symptoms in coronavirus disease 2019: a meta-analysis. *Acta Gastroenterol Belg.* 2020 Oct-Dec;83(4):603-615.
- **Merola E**, Alonso Gordo T, Zhang P, et al. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is  $\geq 10\%$ ? *Oncologist.* 2021 Apr;26(4):294-301. doi: 10.1002/onco.13633. Epub 2020 Dec 29.

- Rogger TM, Michielan A, Sferrazza S, Pravadelli C, Moser L, Agugiaro F, Vettori G, Seligmann S, **Merola E**, et al. Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. *World J Gastroenterol* 2020 Sep 21;26(35):5375-5386.
- Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, **Merola E**, et al. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). *J Endocrinol Invest*. 2020 Aug 16:1-6.
- **Merola E**, Pravadelli C, de Pretis G.. Prevalence of liver injury in patients with coronavirus disease 2019 (COVID-19) : a systematic review and meta-analysis. *Acta Gastroenterol Belg*. 2020 Jul-Sep;83(3):454-460.
- **Merola E**, Dal Buono A, Denecke T, et al. Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. *Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME. Pancreas*. 2020 Aug;49(7):912-917.
- **Merola E**, Falconi M, Rinke A, et al. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. *Am J Surg*. 2020 Aug;220(2):284-289.
- **Merola E**, Zandee WT, de Mestier L, et al. Histopathological Revision for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in Expert Centers: Does it Make the Difference? *Neuroendocrinology*. 2020 Mar 11.
- **Merola E**, Rinke A, Partelli S, et al. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? *Ann Surg Oncol*. 2020 May;27(5):1348-1355.
- **Merola E**, Prasad V, Pascher A, et al. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. *Neuroendocrinology*. 2020;110(6):517-524.
- Gianfranco Delle Fave, **Elettra Merola**, et al. Molecular Pathology of Pancreatic Endocrine Tumors. J.P. Neoptolemos et al. (eds.), *Pancreatic Cancer*, Springer Science+Business Media LLC 2018, [https://doi.org/10.1007/978-1-4939-6631-8\\_7-2](https://doi.org/10.1007/978-1-4939-6631-8_7-2).
- Rinzivillo M, Partelli S, Prosperi D, Capurso G, Pizzichini P, Iannicelli E, **Merola E**, et al. Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms.. *Oncologist*. 2017 Nov 8. pii: theoncologist.2017-0278. doi: 10.1634/theoncologist.2017-0278.
- Panzuto F, Cicchese N, Partelli S, Rinzivillo M, Capurso G, **Merola E**, et al. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. *PLoS One*. 2017 Jun 23;12(6):e0179445.
- **Merola E**, Panzuto F, Fave GD. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. *Oncotarget*. 2017 Mar 29. doi: 10.18632/oncotarget.16686.
- **Merola E**, Pavel M, Panzuto F, et al. Functional imaging in the follow-up of entero-pancreatic neuroendocrine tumors: clinical usefulness and indications. *Journal of Clinical Endocrinology and Metabolism* 2017 Jan 13.
- Panzuto F, **Merola E**, Pavel M, et al. Stage IV gastro-entero-pancreatic neuroendocrine neoplasms: a risk score to predict clinical outcome. *Oncologist* 2017 Feb 23.
- Delle Fave G, **Merola E**, Rinzivillo M. Capitolo: Neuroendocrine tumors, del Libro: Handbook of

Gastroenterology and liver diseases. P.A. Testoni, M. Colombo e UNIGASTRO; Edizioni Minerva Medica ed EGI, 2016

- **Merola E**, Rinzivillo M, Cicchese N, et al. Digestive neuroendocrine neoplasms: a 2016 overview. Dig Liver Dis. 2016 Apr 30. doi: 10.1016/j.dld.2016.04.008.

- **Merola E**, Cao M, La Starza S, et al. Portosystemic encephalopathy in an 86-year-old patient : a clinical challenge. Acta Gastroenterol Belg. 2016 Jan-Mar;79(1):58-9.

- Panzuto F, **Merola E**, Rinzivillo M, et al. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 2014; 43: 212-8. doi: 10.1097/MPA.0000000000000032

- Lineeguida AIOM-ITANET "Neoplasie Neuroendocrine gastroenteropancretiche"; edizione 2013-2015. <http://ita-net.org/news/5>.

- **Merola E**, Sbrozzi-Vanni A, Capurso G, et al. "Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate". Neuroendocrinology 2012;95 :207-13.

- Piciocchi M, **Merola E**, Marignani M, e al. Nasogastric or nasointestinal feeding in severe acute pancreatitis. World J Gastroenterol. 2010 Aug 7;16(29):3692-6.

- **Merola E.**, Capurso G, Campana D, et al. Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Dig Liver Dis. 2010; 42: 457-8.

- Capurso G, Marignani M, Piciocchi M, **Merola E.**, et al. "Probiotics and severe acute pancreatitis". J Clin Gastroenterol 2008;42 Suppl 3 Pt 1:S148-51.

- Capurso G, Marignani M, Piciocchi M, **Merola E.**, et al. Probiotics and severe acute pancreatitis. Addendum. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 1:S152-3.

- **Merola E.**, Claudio PP, Giordano A. "p53 and the malignant progression of Barrett's esophagus". J Cell Physiol 2006; 206: 574-7

- **Merola E.**, Mattioli E, Minimo C, et al. "Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's Esophagus". J Cell Physiol 2006; 207: 512-519 .

**Presentazioni a Congressi**

- Poster al congresso europeo ENETS 2020 (11/03/20 - 13/03/2020), Barcelona, Spagna: **E. Merola**, Alonso Gordo T, Zhang P, et al. "Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is  $\geq 10\%$ ?" (Abstract 3034)
  
- Poster al congresso europeo ENETS 2018 (07/03/18 - 09/03/2018), Barcelona, Spagna: W. Zandee, **E. Merola**, de Mestier L, et al. "Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers" (Abstract 2137)
  
- Presentazione orale come „Invited Speaker“ al congresso europeo ENETS 2018 (07/03/18 - 09/03/2018), Barcelona, Spagna: "Interactive morning workshops 1: Merola E. : Gastroenterologist and Nuclear Medicine View Functional Imaging and PRRT Treatment – When and How Often Is It Really Needed?"
  
- Poster al congresso europeo ENETS 2018 (07/03/18 - 09/03/2018), Barcelona, Spagna: **E. Merola**, W. Zandee, L. de Mestier, H.J. Klumpen, K.P. Geboes, Poczka K, W. de Herder, A. Munir. „Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: does it make the Difference?"
  
- Corso di aggiornamento ECM tedesco "Update Endokrinologie 2017, 04.12.2017, Erlangen Universitaetsklinikum. **Merola E.** : „Neuroendokrine Tumore: neue Entwicklungen“.
  
- Poster at the ASCO conference, Chicago (IL, USA), Giugno 2016: **Merola E**, Pascher A, Denecke T, et al. "Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence"
  
- Poster presentation at the ENETS annual conference (2016), Barcelona, Spain:
  - 1) **Merola E**, Pascher A, Denecke T, et al. "Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence"
  - 2) **Merola E**, Prasad V, Pascher A3, et al. "Peritoneal carcinomatosis in digestive neuroendocrine neoplasms: complications and response to therapy"
  - 3) **Merola E**, Delle Fave G, Blankenstein O, et al. "Chromogranin A in the Follow-up of Digestive Neuroendocrine Neoplasms: is it a useful Biomarker?"
  
- Poster presentation at the ASCO GI Congress, San Francisco (CA, USA), Gennaio 2016: **Merola E**, Panzuto F, Capurso G, et al. " Functional imaging tests vs. CT scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up".
  
- Poster presentation at the AACR Congress, Philadelphia (PA, USA), Aprile 2015: **Merola E**, Panzuto F, Capurso G, et al. " Functional imaging tests vs. CT scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up".
  
- Oral presentation in the Presidential session at the ENETS Congress, Barcelona, March 2015: **Merola E**, Panzuto F, Capurso G, et al. " Functional imaging tests vs. CT scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up".
  
- **Merola E**, Cicchese N, Desideri F, et al.. Role of Somatostatin Receptors scintigraphy in neuroendocrine neoplasms follow-up. (Poster al Congresso FISMAD, Bologna, Marzo 2013)
  
- **Merola E**, Cicchese N, Desideri F, et al.,Role of Somatostatin Receptors scintigraphy in neuroendocrine neoplasms follow-up. (Poster al Congresso dell' " American Pancreatic Association" – APA , Miami, FL, USA, Novembre 2012).
  
- **Merola E**, Cicchese N, Desideri F, et al.,Role of Somatostatin Receptors scintigraphy in neuroendocrine

neoplasms follow-up. (Presentazione orale al Congresso della "United European Gastroenterology Week" – UEGW, Amsterdam, NL, Ottobre 2012).

- **Merola E**, Panzuto F, Rinzivillo M, et al. Metastatic pattern differently affects progression-free survival in pancreatic neuroendocrine tumors (Presentazione del Poster al Congresso della "European Pancreatic Club" - EPC , Praga, Giugno 2012; Comunicazione orale al Congresso FISMAD , Torino 2012).

- **Merola E**, Panzuto F, Rinzivillo M, et al. Advanced digestive endocrine tumors: prognostic factors analysis and patients stratification according to metastatic status (Poster of distinction al Congresso "Digestive Disease Week" – DDW, Maggio 2011, Chicago, IL USA).

- **Merola E**, Sbrozzi-Vanni A, Capurso G, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate (Presentazione orale al Congresso FISMAD a Torino, Marzo 2011, e al congresso "Digestive Disease Week" del 2011, Chicago, IL, USA).

- **Merola E**, Panzuto F, Rinzivillo M, et al. Accuracy of the novel TNM staging system in the prognostic stratification of patients with advanced stage IV digestive endocrine tumors (Poster al Congresso "ESMO GI" del Luglio 2010, Barcellona, Spagna).

- **Merola E**, Panzuto F, Rinzivillo M, et al. Accuratezza del sistema di stadiazione secondo il TNM nella stratificazione prognostica dei pazienti con tumori endocrini digestivi allo stadio IV alla diagnosi (Presentazione orale in plenaria al XVI Congresso Nazionale delle malattie digestive – FISMAD, Verona, Marzo 2010)

- **Merola E**, Sbrozzi-Vanni A, Capurso G, et al. Endoscopic management of type I gastric carcinoid and recurrence rate (Presentazione orale al Congresso "Digestive Disease Week" del 2009, Chicago, IL, USA.).

- Piciocchi M, **Merola E**, Attilia F, et al. Long-term follow-up in an asymptomatic traumatic damage of the main pancreatic duct revealed by an isolated hyperamylasemia (Poster al Congresso AISP, 2008)

- **Merola E**, Piciocchi M, Begini P, et al. Enteral nutrition in severe acute pancreatitis: nasogastric vs nasojejunal tube (Poster al Congresso AISP, Napoli 2007)

- Caviglia R, Ribolsi M, Emerenziani S, Gentile M, **Merola E**, et al. Role of Impaired Epithelial Barrier of Esophageal Body and of Proximal Reflux in the Pathophysiology of Non-Erosive Gastroesophageal Reflux Disease (Presentazione orale in sessione plenaria al Congresso "Digestive Disease Week" del 2004, Chicago, IL, USA)

#### **Esperienza con clinical trials**

- Lexicon LX1606.301
- Radiant IV CRAD001IT2302
- Protocol 8-55-52060-004, phase II study (Ipsen Campanula- study-DOPA-004)
- Clarinet Forte study
- Protocol 8-79-52030-736, SymNET, IPSEN
- PDR001 Study
- COMPETE Study
- EVINEC Study

